[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1105275T1 - Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda - Google Patents

Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda

Info

Publication number
CY1105275T1
CY1105275T1 CY20061101157T CY061101157T CY1105275T1 CY 1105275 T1 CY1105275 T1 CY 1105275T1 CY 20061101157 T CY20061101157 T CY 20061101157T CY 061101157 T CY061101157 T CY 061101157T CY 1105275 T1 CY1105275 T1 CY 1105275T1
Authority
CY
Cyprus
Prior art keywords
competitors
nmda
substituted compounds
lactone substituted
lactone
Prior art date
Application number
CY20061101157T
Other languages
English (en)
Inventor
Corinna Maul
Michael Przewosny
Werner Englberger
Original Assignee
Grunenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grunenthal Gmbh filed Critical Grunenthal Gmbh
Publication of CY1105275T1 publication Critical patent/CY1105275T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση αφορά ενώσεις υποκατεστημένης γαμμα-λακτόνης, μεθόδους δια την παραγωγήν αυτών, φάρμακα τα οποία περιέχουν τις ενώσεις αυτές και τη χρησιμοποίηση των ενώσεων αυτών δια την παραγωγήν φαρμάκων.
CY20061101157T 2001-07-05 2006-08-21 Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda CY1105275T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10132725A DE10132725A1 (de) 2001-07-05 2001-07-05 Substituierte γ-Lactonverbindungen
PCT/EP2002/007380 WO2003004483A1 (de) 2001-07-05 2002-07-03 Substituierte y-lactonverbindungen als nmda-antagonisten

Publications (1)

Publication Number Publication Date
CY1105275T1 true CY1105275T1 (el) 2010-03-03

Family

ID=7690792

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101157T CY1105275T1 (el) 2001-07-05 2006-08-21 Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda

Country Status (11)

Country Link
US (1) US6956055B2 (el)
EP (1) EP1406888B1 (el)
AR (1) AR036130A1 (el)
AT (1) ATE327226T1 (el)
CY (1) CY1105275T1 (el)
DE (2) DE10132725A1 (el)
DK (1) DK1406888T3 (el)
ES (1) ES2266524T3 (el)
PE (1) PE20030275A1 (el)
PT (1) PT1406888E (el)
WO (1) WO2003004483A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US8214813B2 (en) * 2007-01-12 2012-07-03 Microsoft Corporation Code optimization across interfaces
US7985375B2 (en) 2007-04-06 2011-07-26 Qiagen Gaithersburg, Inc. Sample preparation system and method for processing clinical specimens
US8703492B2 (en) 2007-04-06 2014-04-22 Qiagen Gaithersburg, Inc. Open platform hybrid manual-automated sample processing system
KR20180053432A (ko) 2008-08-12 2018-05-21 진판델 파마슈티컬스 인코포레이티드 질환 위험 인자의 식별 방법
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
WO2011063139A1 (en) 2009-11-18 2011-05-26 Qiagen Laboratory central control unit method and system
CN103501783A (zh) 2011-01-10 2014-01-08 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
CN113234036B (zh) * 2021-05-12 2023-07-14 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (en) 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
DE19536809A1 (de) 1995-10-02 1997-04-03 Basf Ag Heterocyclisch substituierte Salicylsäurederivate
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
GB9706294D0 (en) 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound

Also Published As

Publication number Publication date
ES2266524T3 (es) 2007-03-01
AR036130A1 (es) 2004-08-11
WO2003004483A1 (de) 2003-01-16
PT1406888E (pt) 2006-10-31
EP1406888B1 (de) 2006-05-24
DE10132725A1 (de) 2006-08-03
DK1406888T3 (da) 2006-09-18
US20040171677A1 (en) 2004-09-02
DE50206910D1 (de) 2006-06-29
US6956055B2 (en) 2005-10-18
ATE327226T1 (de) 2006-06-15
PE20030275A1 (es) 2003-04-26
EP1406888A1 (de) 2004-04-14

Similar Documents

Publication Publication Date Title
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
CY1110558T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
CY1105275T1 (el) Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda
DE60107687D1 (de) Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
CY1109142T1 (el) Χαρακτηρισμος: σπειροκυκλικα παραγωγα κυκλοεξανιου
CY1106752T1 (el) Διϋδροπτεριδινονες, μεθοδος για την παραγωγη τους και χρηση τους ως φαρμακων
CY1110318T1 (el) Παραγωγα φαινοξυοξικου οξεος
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
CY1108085T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπ-2-εν-1-ονης παρασκευη και χρησης αυτων
CY1108770T1 (el) Νεα παραγωγα του ινδολιου και χρηση τους ως φαρμακων
EA200300937A1 (ru) Оральная фармацевтическая композиция цефподоксима проксетила
CY1113533T1 (el) Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης
ATE412649T1 (de) Substituierte heteroarylbenzofuransäuren
CY1110913T1 (el) Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
NO20050091L (no) Fremgangsmater for fremstilling av fibrinogen
CY1107230T1 (el) Υποκατεστημενες ενωσεις 1-φαιναιθυλοπιπεριδινης, οι οποιες μεταξυ αλλων χρησιμοποιουνται σαν αναλγητικα
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες